Literature DB >> 1826223

Stages of T-cell receptor protein expression in T-cell acute lymphoblastic leukemia.

D Campana1, J J van Dongen, A Mehta, E Coustan-Smith, I L Wolvers-Tettero, K Ganeshaguru, G Janossy.   

Abstract

In this study five monoclonal antibodies (MoAbs) to T-cell receptor (TCR) proteins (WT31, alpha F1, beta F1, TCR delta-1 and delta TCS-1) were used to identify discrete maturative stages in 40 cases of T-cell acute lymphoblastic leukemia (T-ALL). These MoAbs reacted exclusively with CD3+ T cells and did not label B-lineage and myeloid cells. In 17 of the 40 T-ALL cases studied the leukemic blasts lacked membrane and cytoplasmic TCR chains (group I). In 12 cases cells did not have membrane CD3/TCR but expressed cytoplasmic TCR proteins heterogenously: nine cases had cytoplasmic TCR beta chains (beta F1+, alpha F1-; group II), one case had cytoplasmic TCR alpha chains (alpha F1+, beta F1-; group III), and two cases were labeled by both alpha F1 and beta F1 MoAbs (group IV). The remaining 11 cases were mCD3+: nine were TCR alpha beta+ (group Va) and two exhibited TCR gamma delta (TCR delta-1+, delta TCS-1+; group Vb). The analysis of the TCR beta, -gamma, and -delta gene configurations in 23 of the 40 T-ALLs showed that: (1) the lack of TCR protein expression was due to the lack of TCR gene rearrangements only in one of nine cases; (2) five of five TCR beta+, TCR alpha- cases studied had germline TCR alpha genes (ie, no detectable TCR delta gene deletions); (3) seven of eight cases with TCR delta gene deletions expressed TCR alpha proteins, whereas in 12 of 20 of the T-ALLs with TCR beta gene rearrangements the synthesis of the corresponding protein occurred; only 2 of 16 cases with rearranged TCR delta genes expressed TCR delta chains. The T-ALL categories identified with anti-TCR MoAbs did not have additional characteristic phenotypic patterns and may correspond to the normal stages of T-cell development more precisely than those defined by other differentiation antigens.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1826223

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

Review 1.  Chimeric antigen receptor T cell therapies for acute myeloid leukemia.

Authors:  Bin Gu; Jianhong Chu; Depei Wu
Journal:  Front Med       Date:  2020-12-01       Impact factor: 4.592

2.  Characterization of the immunophenotype and the metastatic properties of a murine T-lymphoma cell line. Unexpected expression of cytoplasmatic CD4.

Authors:  C Mongini; P Ruybal; M J Gravisaco; M Croci; M Sánchez Lockhart; V Fabris; A C Waldner
Journal:  In Vitro Cell Dev Biol Anim       Date:  2001-09       Impact factor: 2.416

3.  A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies.

Authors:  Maksim Mamonkin; Rayne H Rouce; Haruko Tashiro; Malcolm K Brenner
Journal:  Blood       Date:  2015-06-08       Impact factor: 22.113

4.  CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies.

Authors:  Diogo Gomes-Silva; Madhuwanti Srinivasan; Sandhya Sharma; Ciaran M Lee; Dimitrios L Wagner; Timothy H Davis; Rayne H Rouce; Gang Bao; Malcolm K Brenner; Maksim Mamonkin
Journal:  Blood       Date:  2017-05-24       Impact factor: 22.113

5.  Characterization of an Anti-CD5 Directed CAR T-Cell against T-Cell Malignancies.

Authors:  Masayuki Wada; Hongyu Zhang; Liu Fang; Jia Feng; Charlotte Olivia Tse; Wenli Zhang; Qi Chen; Sha Sha; Yuanzhen Cao; Kevin H Chen; Kevin G Pinz; Xi Chen; Xing-Xing Fan; Xun Jiang; Yupo Ma
Journal:  Stem Cell Rev Rep       Date:  2020-04       Impact factor: 5.739

6.  Development of chimeric antigen receptors targeting T-cell malignancies using two structurally different anti-CD5 antigen binding domains in NK and CRISPR-edited T cell lines.

Authors:  Sunil S Raikar; Lauren C Fleischer; Robert Moot; Andrew Fedanov; Na Yoon Paik; Kristopher A Knight; Christopher B Doering; H Trent Spencer
Journal:  Oncoimmunology       Date:  2017-12-26       Impact factor: 8.110

Review 7.  Contribution of immunophenotypic and genotypic analyses to the diagnosis of acute leukemia.

Authors:  R Stasi; C G Taylor; A Venditti; G Del Poeta; G Aronica; C Bastianelli; M D Simone; F Buccisano; M C Cox; A Bruno
Journal:  Ann Hematol       Date:  1995-07       Impact factor: 3.673

8.  Harnessing immunotherapy for pediatric T-cell malignancies.

Authors:  Caroline Diorio; David T Teachey
Journal:  Expert Rev Clin Immunol       Date:  2020-02-27       Impact factor: 5.124

Review 9.  Bioinformatic description of immunotherapy targets for pediatric T-cell leukemia and the impact of normal gene sets used for comparison.

Authors:  Rimas J Orentas; Jessica Nordlund; Jianbin He; Sivasish Sindiri; Crystal Mackall; Terry J Fry; Javed Khan
Journal:  Front Oncol       Date:  2014-06-10       Impact factor: 6.244

10.  Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor.

Authors:  K H Chen; M Wada; K G Pinz; H Liu; K-W Lin; A Jares; A E Firor; X Shuai; H Salman; M Golightly; F Lan; L Senzel; E L Leung; X Jiang; Y Ma
Journal:  Leukemia       Date:  2017-01-12       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.